Ask AI
Back Back
Risk Factors for Progression in PBC

CE / CME

Identifying Risk Factors for Disease Progression and Poor Response in PBC: Implications for First-line Therapy

Pharmacists: 0.75 contact hour (0.075 CEUs)

Physicians: maximum of 0.75 AMA PRA Category 1 Credit™

Nurse Practitioners/Nurses: 0.75 Nursing contact hour

Released: March 30, 2026

Expiration: March 29, 2027

Sonal Kumar
Sonal Kumar, MD, MPH
CME/CE Information

Activity

Progress
1 2 3
Course Completed

Dynamics of LSM and Clinical Outcomes in PBC

PBC is a dynamic disease. Studies evaluating changes in liver stiffness have shown that shifts correlate with changes in the risk of liver-related outcomes.

For example, a person who begins with a normal liver stiffness value but later has an increased value during follow-up may be experiencing disease progression. In these situations, an increase in liver stiffness should prompt closer monitoring and consideration of a more aggressive treatment strategy.23

As such, fibrosis assessment should not be viewed as a single time point measurement, especially if there are any additional indicators that a person may be experiencing worsening disease.

Download

UDCA Outcomes by ALP and Total Bilirubin

Advanced fibrosis is an important predictor of disease progression in PBC, but it is not the only one. Baseline ALP and bilirubin, and how ALP and bilirubin levels change over time in response to UDCA treatment, are also key factors that should be considered when evaluating someone’s prognosis.

Long-term follow-up data from the GLOBAL PBC Study Group demonstrate that outcomes are closely associated with ALP and bilirubin levels.8

People who achieve normalization of ALP tend to have the most favorable outcomes. A similar pattern is observed with bilirubin levels ≤0.6 times the ULN.8

Download

Assessing Response: ALP and Bilirubin Combined

Evaluating ALP and bilirubin together can provide an even more nuanced prognosis. These data demonstrate how the combined assessment of biochemical markers provides a useful framework for assessing treatment response and long-term risk.8

For this reason, my treatment goal is to achieve both of these biochemical endpoints whenever possible: normalization of ALP and a bilirubin level ≤0.6 times the ULN.

Download

Biochemical Treatment Response and Fibrosis Stage as Predictors of Transplant-Free Survival

Just as ALP and bilirubin should be evaluated in combination, fibrosis stage and biochemical response should not be considered independently when evaluating patients with PBC. Rather, I believe both factors should be assessed together to better understand a person’s overall risk.

People with early histologic stage at baseline and who achieve a biochemical response to treatment have the most favorable outcomes.15

These data indicate that measuring treatment response alone is not sufficient to understand how a patient will fare in the long term. 

Download

How Low Is Low Enough? ALP Adequate Response vs Normalization

The question that follows is whether we are defining treatment response correctly. What, exactly, is an adequate treatment response?

Several criteria have been proposed to define an adequate biochemical response to treatment in PBC, particularly with respect to ALP. Published response thresholds have ranged from ALP ≤1.67 times the ULN to ≤1.5 times the ULN, or complete normalization.1

The results show that even modest elevations in ALP within the “adequate response” range are associated with worse outcomes compared with complete normalization.9

When biochemical response is considered together with fibrosis stage, people with lower fibrosis burden had better outcomes, even with higher ALP.9

Download

Summary: Identifying Greatest Risk for Disease Progression

Taken together, these baseline and on-treatment factors help guide risk stratification and inform decisions regarding monitoring and treatment intensity.8,9,15,17,19,20

Download

Key Points

To summarize, PBC is a progressive autoimmune liver disease that requires careful risk stratification and monitoring.

Risk assessment should begin at the time of diagnosis and continue throughout the course of the disease using noninvasive tests, biochemical markers, and clinical characteristics such as advanced fibrosis.

All people with PBC should receive first-line therapy with UDCA. However, they should have individualized monitoring based on their risk factors.

Download
Do you plan to make any changes in your clinical practice based on what you learned in today’s program?

Please take a moment to enter 1 key change you plan to make in your clinical practice based on this education.

BACK | NEXT